Latest WuXi PharmaTech Stories
SAN DIEGO and SHANGHAI, June 16, 2013 /PRNewswire/ -- Ambrx and Zhejiang Medicine Co. Ltd. (ZMC) today announced that they have formed a collaboration to develop and commercialize ARX788, Ambrx's most advanced internally developed site-specific antibody drug conjugate (ADC) targeting Her2-positive breast cancer. Under the agreement, Ambrx and ZMC will continue the development of ARX788, with ZMC bearing the ongoing development cost. ZMC will receive commercial rights in China while...
In the news release, "WuXi PharmaTech Announces First-Quarter 2013 Results," issued earlier today by WuXi PharmaTech (Cayman) Inc. over PR Newswire, we are advised by the company that in the section titled "First-Quarter 2013 Non-GAAP Results," the first sentence of the second, third, fourth and fifth paragraphs, "First-quarter 2012" should read "First-quarter 2013"; also, in the second table of the announcement, "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME," "Other...
SHANGHAI, May 13, 2013 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading research and development outsourcing company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States, today announced its financial results for the first quarter of 2013. Highlights Net Revenues Increased 11.7% Year Over Year to $131.9 Million Laboratory Services Net Revenues Grew 12.5% Year Over Year to $97.5 Million...
CHICAGO, April 24, 2013 /PRNewswire/ -- Stocks in this week's article include: Core Laboratories NV (NYSE: CLB), Invesco Ltd. (NYSE: IVZ), Medtronic, Inc. (NYSE: MDT), Willbros Group Inc. (NYSE: WG) and WuXi PharmaTech Inc. (NYSE: WX). Kevin Matras shows how to find companies with accelerated earnings growth. (Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO) Screen of the Week written by Kevin Matras of Zacks Investment Research: In good markets or bad, earnings are one of...
SHANGHAI, April 17, 2013 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX) today announced that it filed its annual report on Form 20-F for the year ended December 31, 2012 with the Securities and Exchange Commission. The annual report can be accessed on WuXi PharmaTech's website at http://www.wuxiapptec.com under the Investor Relations section. WuXi PharmaTech will provide a hard copy of its annual report on Form 20-F containing complete audited financial statements free of...
SHANGHAI, April 10, 2013 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, today announced that it will release financial results for the first quarter of 2013 after the New York Stock Exchange closes on Monday, May 13, 2013 (which will be Tuesday morning, May 14, 2013 Shanghai time). The earnings release will be available on the investor...
Awarded at BioPharma Asia Industry Awards 2013 RALEIGH, N.C., March 25, 2013 /PRNewswire/ -- PRA, a leading clinical research organization, today announced it was voted "Best CRO" for the 3(rd) annual BioPharma Asia Industry Awards 2013. The winner was announced March 19 at an awards dinner in Singapore. "We are deeply honored to have been voted 'Best CRO'," said Kent Thoelke, PRA executive vice president, Scientific and Medical Affairs. "We have been working hard to continually...
SHANGHAI, March 7, 2013 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading research and development outsourcing company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States, today announced its financial results for the fourth quarter and full year of 2012. Fourth-Quarter Highlights Net Revenues Increased 15.8% Year Over Year to $125.7 Million Laboratory Services Net Revenues Grew 18.6% Year...
SHANGHAI and PALO ALTO, Calif., March 5, 2013 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, and Open Monoclonal Technology, Inc. (OMT), an innovator in novel transgenic animals for development of human therapeutic antibodies, today announced a second agreement to expand WuXi's use of OMT's OmniRat(TM) and OmniMouse(TM) technologies to...
SHANGHAI, Feb. 8, 2013 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, today announced that it will release financial results for the fourth quarter of 2012 after the New York Stock Exchange closes on Thursday, March 7, 2013 (which will be Friday morning, March 8, 2013 Shanghai time). The earnings release will be available on the investor...
